INS and cancer: Among female controls, cancer IRs increased across insulin tertiles, ranging from 11.6 cases per 1,000-person-years (95% CI [9.9, 13.7]) in the lowest third to 17.8 cases per 1,000-person-years (95% CI [15.0, 21.2]) in the highest third (Fig 3A).